Cytos Biotechnology AG

DGAP-News: Cytos Biotechnology Ltd - Rights offering oversubscribed - CHF 24.3 million raised

EQS Group-News: Cytos Biotechnology AG / Key word(s): Capital Increase
Cytos Biotechnology Ltd - Rights offering oversubscribed - CHF 24.3
million raised

18.11.2013 / 07:00

---------------------------------------------------------------------

Cytos Biotechnology Ltd:
Rights offering oversubscribed - CHF 24.3 million raised

Schlieren (Zurich), Switzerland, November 18, 2013 - Cytos Biotechnology
Ltd (SIX:CYTN) ('Cytos' or the 'Company') today announced the completion of
a financing transaction that raised a total of CHF 24.3 million by selling
8.1 million shares at a price of CHF 3.00 per share. The rights offering
was oversubscribed and share allocations included the use of authorized
capital. International institutional investors as well as other
shareholders have invested CHF 10.2 million. The group of institutional and
strategic shareholders, Abingworth, Amgen, venBio and Aisling, initially
committed to invest CHF 9 million. Amgen further increased its
participation by CHF 5.1 million, leading to a total investment by this
group of CHF 14.1 million.

Dr. Christian Itin, Chairman and CEO of Cytos, said: 'We appreciate the
continued support of our shareholders and welcome our new investors. Our
ongoing and fully enrolled phase 2b clinical trial with CYT003 is on track
for core data release in April 2014. The additional capital from this
offering supports the development activities for our lead program.'

Further details of the transaction

This financing transaction consisted of a rights offering of 6'303'215
shares to existing shareholders whereby those rights not taken up were
allocated by the Board of Directors to other shareholders or new investors.
In addition, further 1'810'630 shares were placed out of the authorized
share capital. The financing of CHF 24.3 million is in the form of
registered shares issued by Cytos at CHF 3.00 per share and results in an
increase of the issued share capital by a total of 8'113'845 new shares of
Cytos.

For more information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
e-mail: harry.welten@cytos.com

US Investor enquiries
Susan A. Noonan
Tel: +1 (212) 966 3650
susan@sanoonan.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
novel, first-in-class, immune modulator in Phase 2 clinical development as
a potential new treatment for asthma.

CYT003 has a novel mechanism of action that inhibits the immune response
that causes asthma, and may therefore be beneficial for the control of
asthma. In a successfully completed Phase 2a study, CYT003 was shown to
maintain asthma control and lung function in patients with persistent
allergic asthma, despite withdrawal of standard therapy with inhaled
corticosteroids. CYT003 has been shown to have a good safety and
tolerability profile in more than 450 individuals receiving the active
agent so far.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

www.cytos.com

Disclaimer

This document does not constitute a prospectus pursuant to article 652a or
1156 of the Swiss Code of Obligations of article 27 et seq. of the listing
rules of the SIX Swiss Exchange Ltd. A decision to invest in securities of
Cytos Biotechnology Ltd should be based exclusively on the offering and
listing prospectus published by Cytos Biotechnology Ltd for such purpose.

The securities described herein are offered publicly in Switzerland only.
The information contained herein shall not constitute an offer to sell or
the solicitation of an offer to buy, in any jurisdiction in which such
offer or solicitation would be unlawful prior to registration, exemption
from registration or qualification under the securities laws of any
jurisdiction.

This document does not constitute an offer or invitation to subscribe for
or to purchase any securities in the United States of America or any other
jurisdiction. Securities may not be offered or sold in the United States of
America absent registration or an exemption from registration under the
U.S. Securities Act of 1933.

The information contained herein does not constitute an offer of securities
to the public in the United Kingdom. No prospectus offering securities to
the public will be published in the United Kingdom. This document is only
being distributed to and is only directed at (i) persons who are outside
the United Kingdom or (ii) to investment professionals falling within
article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the Order) or (iii) high net worth entities, and
other persons to whom it may lawfully be communicated, falling within
article 49(2)(a) to (d) of the Order (all such persons together being
referred to as 'relevant persons'). The securities are only available to,
and any invitation, offer or agreement to subscribe, purchase or otherwise
acquire such securities will be engaged in only with, relevant persons. Any
person who is not a relevant person should not act or rely on this document
or any of its contents.

Any offer of securities to the public that may be deemed to be made
pursuant to this communication in any Member State of the European Economic
Area (EEA) that has implemented Directive 2003/71/EC (together with the
2010 PD Amending Directive 2010/73/EU, including any applicable
implementing measures in any Member State, the 'Prospectus Directive') is
only addressed to 'qualified investors' within the meaning of the
Prospectus Directive in that Member State.

This media release shall not constitute an offer to sell or the
solicitation of an offer to buy or subscribe for any securities in any
jurisdiction; nor shall part or all of the information herein form the
basis of or be relied on in connection with any investment decision
relating to the securities; nor shall there be any sale of the securities
referred to herein in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration, exemption from registration
or qualification under the securities laws of any such jurisdiction.

Forward Looking Statements

This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements.  You are urged to consider
statements that include the words 'committed', 'could', 'will', 'plans',
'enable', 'expected', 'proposed', 'intends', 'planned,' or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, including that CYT003
may not demonstrate safety or efficacy in clinical trials, that there may
be delays in development or that CYT003 may not receive marketing approval,
and that the Company relies on outside financing to meet capital
requirements, which may not be available under acceptable terms or at all.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.


End of Corporate News

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=NEFQUEWYMO
Document title: Cytos_Press_E_131118

---------------------------------------------------------------------

18.11.2013 This Corporate News was distributed by EQS Schweiz AG.
www.eqs.com - news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
             Switzerland
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
E-mail:   info@cytos.com
Internet: www.cytos.com
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Freiverkehr in Berlin, München, Stuttgart; Frankfurt in
             Open Market ; SIX


End of News    EQS Group News-Service
---------------------------------------------------------------------
240316 18.11.2013
 

 


Das könnte Sie auch interessieren: